Elevance Health, Inc. $ELV Shares Purchased by National Pension Service

National Pension Service grew its position in shares of Elevance Health, Inc. (NYSE:ELV) by 2.6% during the 3rd quarter, Holdings Channel reports. The firm owned 550,197 shares of the company’s stock after purchasing an additional 13,802 shares during the period. National Pension Service’s holdings in Elevance Health were worth $177,780,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in Elevance Health in the second quarter worth about $1,148,379,000. Sanders Capital LLC boosted its position in shares of Elevance Health by 24.7% during the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after purchasing an additional 1,152,440 shares in the last quarter. Beutel Goodman & Co Ltd. acquired a new position in shares of Elevance Health in the 2nd quarter worth approximately $293,141,000. Vanguard Group Inc. raised its holdings in shares of Elevance Health by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after purchasing an additional 704,790 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Elevance Health by 30.7% during the second quarter. The Manufacturers Life Insurance Company now owns 2,076,668 shares of the company’s stock valued at $807,741,000 after purchasing an additional 487,579 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 0.4%

Shares of NYSE ELV opened at $345.62 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The business has a 50-day moving average price of $351.69 and a two-hundred day moving average price of $328.98. The firm has a market capitalization of $76.81 billion, a PE ratio of 13.76, a PEG ratio of 1.88 and a beta of 0.51.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Analysts Set New Price Targets

ELV has been the topic of several recent research reports. Jefferies Financial Group decreased their price target on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research report on Friday. Barclays cut their target price on Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a research report on Friday. Mizuho set a $413.00 price target on Elevance Health in a research report on Friday, January 9th. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Finally, Guggenheim cut their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $396.90.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.